Oxford Brain Diagnostics Ltd. news

Approximately 201 patients will be enrolled to study the XPro™ intervention. The objectives of this study are to determine the safety, tolerability, and efficacy of XPro™ in patients with mild AD.

Oxford, UK, 29th March 2022. Oxford Brain Diagnostics, a software company focused on developing diagnostics that identify changes in the brain at a cellular level, today announced that their Cortical Disarray Measurement (CDM®) has been appointed as a secondary outcome measur

Oxford Brain Diagnostics team are really looking foward to attending ADPD2022 this year. We invite all our colleagues, friends and collaborators to listen into our talk. Its starts at 18:45 (CET) 17th March 2022. - `Novel in vivo cortical diffusion MRI measures correlate with classical neuropathology across the #alzheimers continuum in an autopsy confirmed cohort`.

Oxford Brain Diagnostics Ltd, a software company focused on developing diagnostics based on changes in the brain at the cellular level, is delighted to announce that we have established a research collaboration with Principal Investigator Dr Takashi Nakajima, MD, PhD at Niigata Hospital and Dr Kazuo Shigematsu at Minami Kyoto National Hospital. In Japan, clinical MRI scanners are available for the diagnosis and evaluation of dementia. Brain imaging by MRI is available for patients with dement

Oxford Brain Diagnostics Ltd, a software company focused on developing diagnostics based on changes in the brain at the cellular level, is delighted to announce that we have been awarded funding by the National Institute for Health Research (NIHR) to assess CDM® as a novel and promising tool to identify and predict disease progression amongst patients presenting with mild cognitive impairment due to Alzheimer’s disease. This multi-centre project, led by Oxford Brain Diagnostics, inc

Oxford Brain Diagnostics Ltd, a spinout from the University of Oxford specialising in the measurement of neurodegeneration in Alzheimer’s disease, today announces that the US Food and Drug Administration (FDA) has awarded Breakthrough Device Designation to its Cortical Disarray Measurement (CDM®) Software Device for evaluating adults at risk of Alzheimer’s disease

Oxford Brain Diagnostics’ first product from its software platform seeks to be a breakthrough in the

Oxford Brain Diagnostics has started a project for Takeda Pharmaceuticals.

The project is testing Cortical Disarray Measurement (CDM®) technology as a neurodegeneration biomarker with a view to using it in future clinical trials.

Dr Steven Chance, CEO, said ‘we are very excited to be engaged with Takeda on this project using our CDM method on diffusion MRI scans. Alzheimer’s remains a complex condition so exploring the disease

Dr Steven Chance, Chief Executive Officer, is invited back to Japan by NHO Neurology Research Group to speak on the role of CDM as a potential clinical tool for the detection of dementia.

OBD becomes a member of the CPAD Initiative. This consortium works with industry, regulatory authorities, and patient advocacy organisations to advance Drug Development Tools (DDTs) for evaluating drug efficacy and safety.